Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study

BACKGROUND: Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib have demonstrated encouraging activity in prolonging progression‐free survival (PFS) in several bone sarcoma entities in prospective clinical trials. This retrospective study aims to analyze the safety and efficacy of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhiyong, Gao, Songtao, Zhu, Liangyu, Wang, Jiaqiang, Zhang, Peng, Li, Po, Zhang, Fan, Yao, Weitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559478/
https://www.ncbi.nlm.nih.gov/pubmed/34564939
http://dx.doi.org/10.1002/cam4.4286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559478/
https://www.ncbi.nlm.nih.gov/pubmed/34564939
http://dx.doi.org/10.1002/cam4.4286

Ejemplares similares